| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christopher A Lieu, Thyagarajan Subramania. The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias. Brain research bulletin. vol 87. issue 1. 2012-05-17. PMID:21963946. |
we have recently shown that clinically hemiparkinsonian rhesus monkeys do not develop levodopa-induced dyskinesias despite chronic intermittent exposure and significant unilateral loss of nigrostriatal neurons and dopamine. |
2012-05-17 |
2023-08-12 |
rat |
| Véronique Sgambato-Faure, Maria Angela Cenc. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. vol 96. issue 1. 2012-05-07. PMID:22075179. |
glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of parkinson's disease. |
2012-05-07 |
2023-08-12 |
rat |
| Véronique Sgambato-Faure, Maria Angela Cenc. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. vol 96. issue 1. 2012-05-07. PMID:22075179. |
dyskinesias represent a major complication of dopamine replacement therapy in parkinson's disease (pd) and have prompted a search for alternative treatments. |
2012-05-07 |
2023-08-12 |
rat |
| Véronique Sgambato-Faure, Maria Angela Cenc. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Progress in neurobiology. vol 96. issue 1. 2012-05-07. PMID:22075179. |
accumulating evidence indicates that dyskinesias induced by stn-hfs and dopamine replacement therapy are linked to dysregulation of glutamate transmission in the basal ganglia. |
2012-05-07 |
2023-08-12 |
rat |
| Juan Carlos Giugni, Lorena Tschopp, Victoria Escalante, Federico Michel. Dose-dependent impulse control disorders in piribedil overdose. Clinical neuropharmacology. vol 35. issue 1. 2012-05-07. PMID:22240861. |
during an examination, mild dyskinesia was evident.we diagnosed icds and most likely dopamine dysregulation syndrome dds. |
2012-05-07 |
2023-08-12 |
dog |
| Hsien-yang Lee, Junko Nakayama, Ying Xu, Xueliang Fan, Maha Karouani, Yiguo Shen, Emmanuel N Pothos, Ellen J Hess, Ying-Hui Fu, Robert H Edwards, Louis J Ptáce. Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. The Journal of clinical investigation. vol 122. issue 2. 2012-04-20. PMID:22214848. |
dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia. |
2012-04-20 |
2023-08-12 |
mouse |
| Christopher Kobylecki, Michael P Hill, Alan R Crossman, Paula Ravenscrof. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 26. issue 13. 2012-04-05. PMID:21953539. |
topiramate and amantadine exhibited differential antidyskinetic effects on dyskinesia elicited by the dopamine d1 receptor agonist skf 38393 (2 mg/kg). |
2012-04-05 |
2023-08-12 |
rat |
| Lin-Lin Yin, Xing-Chao Geng, Xing-Zu Zh. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model. Brain research bulletin. vol 86. issue 5-6. 2012-04-05. PMID:21963945. |
chronic dopamine (da) replacement therapy with l-3,4-dihydroxyphenylalanine (l-dopa) in parkinson's disease (pd) often leads to abnormal involuntary movements (aims) known as l-dopa-induced dyskinesia (lid), mediated by da receptors. |
2012-04-05 |
2023-08-12 |
rat |
| Adjmal Nahimi, Mette Høltzermann, Anne M Landau, Mette Simonsen, Steen Jakobsen, Aage Kristian Olsen Alstrup, Kim Vang, Arne Møller, Gregers Wegener, Albert Gjedde, Doris J Doude. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning. Journal of neurochemistry. vol 120. issue 5. 2012-04-05. PMID:22117574. |
recent studies suggest that l-3,4 dihydroxyphenylalanine (l-dopa)-induced dyskinesia (lid), a severe complication of conventional l-dopa therapy of parkinson's disease, may be caused by dopamine (da) release originating in serotonergic neurons. |
2012-04-05 |
2023-08-12 |
rat |
| Manfred Gerlach, Gerd D Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buus. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21253782. |
role of dopamine d3 and serotonin 5-ht 1a receptors in l: -dopa-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of parkinson's disease. |
2012-03-30 |
2023-08-12 |
rat |
| P Jenner, A C McCreary, D K A Schelle. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21881838. |
dyskinesia is more commonly induced by l: -dopa than by dopamine agonist drugs. |
2012-03-30 |
2023-08-12 |
Not clear |
| Mahmoud M Iravani, Peter Jenne. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21881839. |
a significant proportion of patients with parkinson's disease (pd) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment. |
2012-03-30 |
2023-08-12 |
Not clear |
| Mahmoud M Iravani, Peter Jenne. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. Journal of neural transmission (Vienna, Austria : 1996). vol 118. issue 12. 2012-03-30. PMID:21881839. |
there is increasing evidence for the role of serotoninergic neurones in dyskinesia induction related to non-physiological formation and release of dopamine and serotoninergic agonists can modify dyskinesia expression. |
2012-03-30 |
2023-08-12 |
Not clear |
| M Carta, E Bezar. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience. vol 198. 2012-03-22. PMID:21840375. |
positron emission tomography (pet) imaging studies have shown that peak-dose dyskinesia is associated to abnormally high levels of synaptic dopamine (da) in the caudate-putamen of dyskinetic l-dopa-treated patients. |
2012-03-22 |
2023-08-12 |
rat |
| Xiu-Ying Cai, Xiao-Ming Kong, Qi Fang, Ping Ning, Yu-Jie Xu, Bin Zhang, Shou-Ru Xu. An autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of Parkinson's disease. Neuro-degenerative diseases. vol 9. issue 1. 2012-03-20. PMID:21876323. |
an autoradiographic study on the pathogenesis of levodopa-induced dyskinesia: regulation of dopamine transporter by levodopa in a rat model of parkinson's disease. |
2012-03-20 |
2023-08-12 |
rat |
| Michael W Jan. Advanced strategies for treatment of Parkinson's disease: the role of early treatment. The American journal of managed care. vol 17 Suppl 12. 2012-03-20. PMID:22087552. |
other therapies, including dopamine agonists and monoamine oxidase type-b (mao-b) inhibitors, may limit the rate of dyskinesia relative to levodopa-based regimens. |
2012-03-20 |
2023-08-12 |
Not clear |
| M S Lue. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications. Pharmacotherapy. vol 19. issue 11 Pt 2. 2012-03-09. PMID:10555945. |
variations in levodopa delivery and subsequent dopamine exposure may lead to motor fluctuations and dyskinesias in patients with parkinson's disease, as the therapeutic window for levodopa narrows with disease progression. |
2012-03-09 |
2023-08-12 |
Not clear |
| Amandine Berthet, Erwan Bezard, Gregory Porras, Stefania Fasano, Pedro Barroso-Chinea, Benjamin Dehay, Audrey Martinez, Marie-Laure Thiolat, Marika Nosten-Bertrand, Bruno Giros, Jérôme Baufreton, Qin Li, Bertrand Bloch, Marie-Laure Martin-Negrie. L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 32. issue 2. 2012-03-06. PMID:22238104. |
aberrant membrane localization of dopamine d(1) receptor (d1r) is associated with l-dopa-induced dyskinesia (lid), a major complication of l-dopa treatment in parkinson's disease (pd). |
2012-03-06 |
2023-08-12 |
mouse |
| Cristina Miguelez, Asier Aristieta, Maria Angela Cenci, Luisa Uged. The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. PloS one. vol 6. issue 9. 2012-02-28. PMID:21931808. |
l-dopa-induced dyskinesia is attributed to a dysregulated dopamine transmission within the basal ganglia, but serotonergic and noradrenergic systems are believed to play an important modulatory role. |
2012-02-28 |
2023-08-12 |
rat |
| Yoshihisa Tachibana, Hirokazu Iwamuro, Hitoshi Kita, Masahiko Takada, Atsushi Namb. Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia. The European journal of neuroscience. vol 34. issue 9. 2012-02-17. PMID:22034978. |
we found that systemic administration of l-3,4-dihydroxyphenylalanine (l-dopa; dopamine precursor) decreased abnormal neuronal oscillations (8-15 hz) in the internal segment of the globus pallidus (gpi) and the subthalamic nucleus (stn) during the on state when parkinsonian signs were alleviated and during l-dopa-induced dyskinesia. |
2012-02-17 |
2023-08-12 |
monkey |